Brentuximab Vedotin with Re-induction Chemotherapy Effective, Well Tolerated in AML

A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia.

Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news